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Abstract
Purpose: To define global transcriptional responses of Staphylococcus aureus and its codY mutant (CodY is a transcription
regulator of virulence and metabolic genes in response to branched-chain amino acids) when growing in bovine aqueous
(AH) and vitreous humor (VH) in vitro, and to investigate the impact of codY deletion on S. aureus virulence in a novel
murine anterior chamber (AC) infection model.
Methods: For the in vitro model, differential transcriptomic gene expression of S. aureus and its codY mutant grown in
chemically defined medium (CDM), AH, and VH was analyzed. Furthermore, the strains were inoculated into the AC of mice.
Changes in bacterial growth, electroretinography and inflammation scores were monitored.
Results: Bovine AH and VH provide sufficient nutrition for S. aureus growth in vitro. Transcriptome analysis identified 72
unique open reading frames differentially regulated $10-fold between CDM, AH, and VH. In the AC model, we found
comparable growth of the codY mutant and wild type strains in vivo. Average inflammation scores and retinal function were
significantly worse for codY mutant-infected eyes at 24 h post-infection.
Conclusion: Our in vitro bovine AH and VH models identified likely nutrient sources for S. aureus in the ocular milieu. The
in vivo model suggests that control of branched-chain amino acid availability has therapeutic potential in limiting S. aureus
endophthalmitis severity.
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Introduction
Staphylococcus aureus is a commensal bacterium on the skin
and mucosa, but is also a leading cause of infections in humans.
When opportunistic pathogens infect sterile sites, they adapt,
proliferate in the host, and exhibit virulence. The host becomes the
sole source for nutrients. For many gram-positive bacteria, CodY
provides an important regulatory link between nutrient availability
and virulence factor production [1]. CodY controls expression of
virulence and metabolic genes in response to the availability of
branched-chain amino acids (BCAA) and GTP through Agr, a
global regulator of the staphylococcal virulon [2]. In the presence
of GTP and/or BCAA, CodY shows a higher affinity for its DNA
targets, while in the absence of nutrients, there is a decrease in the
GTP and BCAA levels causing decreased affinity of CodY to the
DNA and thus induction of its regulon. In S. aureus, CodY
regulates its regulon either indirectly via the quorum sensing
regulator Agr or independent of the Agr system and through its
direct binding to its DNA targets [2]. In general, CodY-regulated
genes trigger adaptation to starvation [2–9] as well as play a role in
virulence of pathogenic bacteria [3,4,10].
The human eye as well as eyes of animals like rabbits and mice
possess sterile anterior and posterior compartments, which contain
aqueous and vitreous humor, respectively. Infectious endophthal-
mitis [inflammation within the eye) is a complication of
penetrating trauma to the eye and intraocular procedures such
as cataract surgery that can lead to blindness [11–14]. The visual
prognosis following infection depends greatly on the virulence of
the causative organism, visual acuity at presentation, and the
efficacy of antimicrobial treatment [15]. S. aureus is the second
most common cause of acute postoperative infection following
intraocular surgeries and is also associated with significant visual
loss [15]. Given the presence of BCAA in human aqueous and
vitreous humors [16,17] and the findings that CodY controls
directly and indirectly S. aureus virulence genes such as hla and
agr [1,2] which contribute to virulence in animal models of
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e110872endophthalmitis [18,19], CodY may play a role in regulating S.
aureus virulence during endophthalmitis.
S. aureus growth and virulence in animal models of endoph-
thalmitis has been assessed, most frequently by intravitreal
(posterior chamber) injection [18,19]. S. aureus strains grow
in vivo to different extents, depending on the strain used and the
inoculation site (anterior versus posterior compartments) [20,21].
For example, following injection into the anterior chamber, Balzli,
et al. found that among 9 S. aureus isolates injected into the
anterior chamber of rabbit eyes, only one strain, UMCR1, grew
[20]. Wu, et al. [21] and Kowalski, et al. [22] found that S. aureus
grew in the anterior chamber of rabbits, and used that model to
test antibiotic efficacies. Several other studies have found that S.
aureus can grow to high densities in the vitreous, and studied the
contribution of toxins, the global virulence regulators Agr and Sar
[18,23], and other cell wall components to pathogenesis. S. aureus
clearly survives in the human eye, given that S. aureus can be
recovered from the aqueous and vitreous humors of patients who
develop endophthalmitis [24]. It is unknown what nutrient sources
S. aureus utilizes during infection of the human eye. In this study,
we use aqueous and vitreous fluids extracted from commercially-
obtained bovine eyes as ex vivo endophthalmitis models for S.
aureus, and define global transcriptional responses of S. aureus to
growth in these media. Our goal was to identify genes that are
consistently and highly differentially regulated by S. aureus during
growth in pooled bovine AH and VH samples. We additionally
interrogate the impact of codY deletion on S. aureus gene
expression during growth in these media, as well as its impact on
S. aureus virulence in a novel murine anterior chamber (AC)
infection model.
Materials and Methods
Strains and growth media
S. aureus strains used are listed in Table 1. S. aureus was
routinely cultured in brain heart infusion (BHI) or on BHI agar.
All cultures were incubated at 37uC. For microarray experiments,
S. aureus were grown in chemically defined Socransky’s medium
[25] supplemented with 20 mM glucose (referred to here as
CDM), or bovine aqueous or vitreous humor (AH and VH,
respectively). CDM contains 76 mM leucine, 85 mM valine, and
76 mM isoleucine. Bacterial growth was assessed by monitoring
optical density at 600 nm (OD600) using a Biotech Synergy 2
microplate reader or by serial dilution and plating on BHI agar to
obtain colony forming units per milliliter (CFU/mL).
Bovine AH and VH collection
AH and VH were extracted from commercially available bovine
eyes (Sierra for Medical Science, Whittier, CA) and pooled as
described previously [26]. Typical volumes of AH and VH
recovered per bovine eye were 0.5–1 mL and 3–4 mL, respec-
tively. AH was filter-sterilized with a 0.45 mm HT Tuffryn
membrane sterile acrodisc syringe filter (Pall Life Sciences,
Batavia, IL). VH was filter-sterilized with a 0.45 mm PES sterile
filter (Whatman, Clifton, NJ). Sterile AH and VH were stored at
280uC until use. For microarray experiments, aspirates were
pooled to a total of 40 mL achieve adequate volume.
Microarray analysis
S. aureus strains were struck from freezer stock onto BHI agar
and incubated overnight. Colonies were used to inoculate CDM,
AH or VH broth cultures, which were incubated overnight and
then used to inoculate new CDM, AH and VH broth cultures to
an initial OD600 of 0.02–0.03. Bacteria were harvested for
microarray analysis and semi-quantitative RT-PCR analyses
during exponential growth, at an OD600 of 0.4–0.5 for CDM
and 0.15–0.2 for AH and VH. Cells were stabilized with
RNAProtect (Qiagen) and RNA was extracted using the RNA
Bee reagent (TelTest, Inc.) per the manufacturer’s instructions.
Absence of DNA contamination was verified by PCR using
primers targeting the 16S rRNA gene (For, 59-AAC TCT GTT
ATT AGG GAA GAA C-39; Rev, 59-CCA CCT TCC TCC
GGT TTG TCA CC-39). cDNA synthesis, fragmentation, biotin
labeling and hybridization to Affymetrix S. aureus GeneChips
were performed as previously described [27]. Hybridization and
scanning of GeneChips were performed at the University of Iowa
DNA Core. Microarray experiments were performed in duplicate.
Affymetrix GeneChip data was analyzed with GeneChip Oper-
ating Software (GCOS version 1.4). Probe sets with statistically
significant change calls (increased or decreased; p#0.05) between
control and test conditions were considered for further analysis,
and fold change cut-offs were applied as described in the text.
Microarray data have been deposited in ArrayExpress under
accession numbers E-MTAB-2928.
For the Affymetrix S. aureus GeneChip, probe set IDs (for
example, sa_c10261s8939_a_at) are used instead of gene names or
ORF designations. To convert probe set IDs to genomic loci, we
downloaded target DNA sequences corresponding to differentially
expressed probe sets from the NetAffx Analysis Center (www.
affymetrix.com/analysis/index.affx). Target sequences were com-
pared to available S. aureus sequences in GenBank using NCBI
BLAST (http://blast.ncbi.nlm.nih.gov). Transcription unit and
metabolic pathway predictions were obtained from the BioCyc
Staphylococcus aureus COL database (http://biocyc.org/
organism-summary?object=SAUR93062). Where appropriate,
predicted protein products of differentially expressed genes were
analyzed for putative functions using NCBI protein BLAST and
Pfam 26.0 (http://pfam.janelia.org). Subcellular localization of
proteins was predicted using PSORTb version 3.0 (http://www.
psort.org/).
Semiquantitative RT-PCR
Semiquantitative reverse transcription (RT)-PCR was per-
formed using Superscript II reverse transcriptase as outlined by
the manufacturer (Invitrogen). S. aureus RNA was used to make
cDNA with priming by random hexamers. cDNA was purified
Table 1. Bacterial strains used in this study.
S. aureus strain Description Reference/source
SA564 Clinical isolate [48]
CDM7 SA564 DcodY::ermC [29]
MS7 SA564 DcodY::ermC pTL6936-codY [29]
doi:10.1371/journal.pone.0110872.t001
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resulting purified cDNA was used as template in a 25 ml standard
PCR reaction with Taq polymerase (New England Biolabs). For
visualization, 5 ml of the PCR reaction was analyzed using agarose
gel electrophoresis with ethidium bromide. The housekeeping
gene clpX was used as a control for gene expression. Expression of
tst, cidA and nanA was evaluated. Those genes were chosen based
on their significant differential regulation across media (nanA was
54.8 in AH vs DM; cidA was 12.8 in VH vs DM; tst was 15.2 in
AH vs DM). An independent set of pooled fluids was used for this
experiment.
Murine AC infection model
Female C57BL/6J mice were obtained from the Charles River
Laboratory (Boston, MA). All animals were treated according to
the guidelines of the Association for Research in Vision and
Ophthalmology Resolution on the Use of Animals in Research.
The protocol was approved by Massachusetts Eye and Ear
Infirmary’s Institutional Animal Care and Use Committee
(IACUC). Mice were anesthetized by intraperitoneal injection of
ketamine (62.5 mg/kg) and xylazine (12.5 mg/kg). Animals were
euthanized at the appropriate time points by CO2 asphyxiation.
S. aureus colonies obtained after growth on BHI agar were
cultured overnight in BHI broth and subcultured 1:500 with fresh
BHI broth and grown to an OD600 nm of 0.4–0.8, pelleted by
centrifugation at 10,000 rpm, and washed twice with PBS. The
ACs of the right eyes of 6–8-week-old female mice were inoculated
with 1 mLo fS. aureus culture using 35 gauge needle on a nanofil
syringe (World Precision Instruments, Inc.), just anterior to the
limbus without touching the iris. For S. aureus MS7, 2 mM
isopropyl b-D-1-thiogalactopyranoside (IPTG) was added to
subcultures and included in PBS washes. The left eyes were left
untreated and served as internal controls for electroretinography
(ERG). Experiments were performed at least in duplicate with a
minimum of 3 animals per experimental group. Animals were
given water with 12 mM IPTG for one week prior to infection
with S. aureus MS7. Quantification of in vivo bacterial growth,
slitlamp examination and ERG were performed as described
previously [28]. Briefly, intraocular inflammation was graded
using the following criteria: 0, normal; 1, small amount of fibrin on
the pupil; 2, iris partially covered with fibrin and/or hypopyon; 3,
iris covered with fibrin and/or hypopyon; 4, pupil not visible. The
retinal function in the infected eye was measured using ERG and
was defined as the ratio of the b-wave (measured from the trough
of the a-wave to the peak of the b-wave) amplitude of the
experimentally treated eye to that of the contralateral untreated
eye, times 100.
Histological analysis
Enucleated eyes were fixed in buffered formalin solution and
histological analysis was performed by Excalibur Pathology Inc.
(Oklahoma City, OK). Pathology slides were examined for signs
and extent of inflammation in the different compartments of the
eye, and disruption in retinal architecture.
Statistical analysis
Normality tests were performed on all data sets. The data were
analyzed with an unpaired t-test if the distribution was Gaussian,
or with the nonparametric Mann-Whitney test if the data were not
normally distributed. P#0.05 was set as the basis for rejection of
Figure 1. S. aureus growth in CDM, AH and VH. S. aureus SA564
(black circles), CDM7 (white squares), and MS7 (grey triangles) were
grown in CDM, AH, or VH, as described in the text. Growth was
monitored by optical density at 600 nm (OD600 nm). Representative
growth curves are shown. Arrows indicate time points where microarray
sampling occurred.
doi:10.1371/journal.pone.0110872.g001
In Vitro and In Vivo S. aureus Endophthalmitis Models
PLOS ONE | www.plosone.org 3 October 2014 | Volume 9 | Issue 10 | e110872Table 2. Transcriptomes of AH- and VH-grown S. aureus SA564.
ORF/intergenic region
a Gene
a Description of gene or queried region
AH vs DM Fold
change
b







Genes putatively involved in nutrient transport or metabolism
SACOL0154 aldA1 Aldehyde dehydrogenase 13.2 (3.3) 5.0 (1.1)
SACOL0173 ipdC Indole-3-pyruvate decarboxylase 12.1 (2.2) 12.1 (1.3)
SACOL0176 Conserved hypothetical protein 42.2 (1.1) 3.9 (1.3) 210.9 (1.3)
SACOL0177 murQ Glucokinase regulator-related protein 27.4 (1.2) 211.5 (1.2)
SACOL0178
e PTS system, IIBC components 21.1 (1.2) 28.3 (1.3)
SACOL0179 Phosphosugar-binding transcriptional
regulator, RpiR family
12.1 (1.2) 26.2 (1.5)
SACOL0192 Maltose ABC transporter, ATP-binding protein, putative 21.5 (1.5) 26.5 (1.6)
SACOL0193 Maltose ABC transporter, maltose-binding
protein, putative
14.4 (1.3) 3.4 (1.2) 24.2 (1.4)
SACOL0194 Maltose ABC transporter permease protein 11.1 (1.5) 3.3 (1.4) 23.7 (1.4)
SACOL0195 Maltose ABC transporter permease protein 13.9 (1.5) 3.7 (1.4) 23.4 (1.5)
SACOL0196 Oxidoreductase, Gfo/Idh/MocA family 12.6 (1.5) 3.3 (1.3) 23.9 (1.5)
SACOL0197 Oxidoreductase, Gfo/Idh/MocA family 10.2 (1.4) 3.2 (1.1) 23.2 (1.4)
SACOL0198 Conserved hypothetical protein 10.7 (1.4) 3.1 (1.3) 23.1 (1.2)
SACOL0200
e Phosphoglycerate transporter family protein 44.5 (1.4) 227.9 (1.6)
SACOL0204 pflB Formate acetyltransferase 16.0 (2.7) 24.4 (2.0)
SACOL0205 pflA Pyruvate formate-lyase-activating enzyme 11.5 (2.5) 4.3 (1.8)
SACOL0215 Propionate CoA-transferase, putative 10.7 (1.4)
SACOL0308
e (yeiC) Carbohydrate kinase, PfkB family 54.8 (1.5) 240.1 (1.8)
SACOL0309 (yeiN) Conserved hypothetical protein 45.3 (1.6) 238.7 (1.7)
SACOL0310 (yeiM) Nucleoside permease NupC, putative 28.3 (2.1) 232.0 (1.7)
SACOL0311 nanT Sodium:solute symporter family protein 38.1 (1.7) 213.2 (1.7)
SACOL0312 nanA N-acetylneuraminate lyase 54.8 (1.7) 3.5 (1.3) 214.4 (1.7)
SACOL0400 (ulaA) Transport protein SgaT, putative 13.7 (1.4) 212.6 (1.4)
SACOL0401 (ulaB) Conserved hypothetical protein 20.7 (1.4) 216.0 (1.5)
SACOL0402 (ulaC) PTS system, IIA component 29.3 (1.4) 223.8 (1.4)
SACOL0403 Transcriptional antiterminator, BglG
family
28.3 (1.4) 228.3 (1.6)
ig_SACOL0913 Intergenic region downstream of
SACOL0913
215.2 (1.9) 26.3 (2.4)
SACOL0960 rocD2 Ornithine aminotransferase 10.0 (2.0) 3.5 (1.2)
SACOL1360 Aspartate kinase 10.6 (5.9) 6.0 (1.3)
SACOL1734 gapA2 Glyceraldehyde-3-phosphate dehydrogenase 10.4 (4.9) 26.8 (4.9)
SACOL1784 acuA Acetoin utilization protein AcuA 13.7 (3.6)
SACOL1785 Acetoin utilization protein AcuC 10.6 (3.2)
SACOL1816 putA Proline dehydrogenase 21.1 (1.7) 3.7 (1.4) 25.4 (1.7)
SACOL2163 Conserved hypothetical protein 11.7 (1.4) 7.2 (1.5)
SACOL2247 Hypothetical protein 219.7 (7)
SACOL2356 ABC transporter, ATP-binding protein 210.0 (2.7)
SACOL2357 ABC transporter, permease protein 210.6 (2.9)
SACOL2403 ABC transporter, substrate binding
protein
26.7 (1.5) 215.7 (1.5)
SACOL2415 gpm Phosphoglycerate mutase 10.9 (1.7) 12.1 (1.6)
SACOL2427 bioA Adenosylmethionine-8-amino-7-oxononanoate
aminotransferase
8.3 (3.5) 13.9 (1.5)
SACOL2428 bioD Dethiobiotin synthase 16.0 (3.9) 24.3 (1.7)
SACOL2441 Amino acid permease 10.6 (4.4) 3.9 (1.7)
SACOL2527 Fructose-1,6-bisphosphatase, putative 11.3 (2) 6.7 (1.2)
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aid of the Harvard Catalyst Biostatistical Consulting Program.
Results
S. aureus SA564 in vitro growth in bovine AH and VH
S. aureus SA564 is a clinical isolate that was previously used to
evaluate a role for codY in S. aureus virulence regulation [29]. As a
first step in understanding S. aureus physiology and metabolism
during endophthalmitis, we evaluated S. aureus SA564 growth in
pooled AH and VH harvested from commercially obtained bovine
eyes. S. aureus SA564 was also grown in Sokransky’s medium, a
buffered, defined medium supplying amino acids, vitamins,
nucleobases, metals, and other growth factors [25], supplemented
with 20 mM glucose as a carbon source. For the purposes of this
manuscript, Sokransky’s medium with 20 mM glucose is referred
to as CDM. Representative growth curves for S. aureus SA564 as
assessed by OD600 nm are shown in Fig. 1. These data demonstrate
that CDM, pooled bovine AH, and pooled bovine VH support
in vitro growth of S. aureus SA564. We reproducibly observed a
clumping phenotype early in S. aureus in vitro AH growth,
resulting in reduced cell density measurements obtained by OD600
nm, as shown in Fig. 1. Also of note, one pooled AH sample did not
support robust S. aureus in vitro growth (data not shown), possibly
as a result of antimicrobials such as antibiotics or inflammatory
factors present in one or more individual AH samples. We were
unable to obtain additional information from the vendor about the
health and history of cows used in this study.
Transcriptome analysis of AH- and VH-grown S. aureus
SA564
We used Affymetrix GeneChips to examine gene expression of
S. aureus SA564 during growth in bovine AH and VH, using
CDM-grown SA564 as a control. Cells were harvested for
microarray analysis during exponential growth; representative




a Description of gene or queried region
AH vs DM Fold
change
b







Putative or confirmed virulence and biofilm factors
SACOL0247 lrgA Holin-like protein LrgA 7.0 (3.8) 214.4 (4.0)
SACOL0248 lrgB LrgB protein 6.3 (4.1) 211.1 (3.8)
SACOL1187 Antibacterial protein (phenol soluble modulin) 10.4 (2.5) 26.5 (1.8)
SACOL2509 fnbB Fibronectin binding protein B 213.0 (1.3)
SACOL2554_1 cidA LrgA family protein 12.8 (1.4) 34.9 (1.4)
SACOL2652 clfB (rev comp) Queries 97 nt region complementary
to the 59 end of clfB (clumping factor B)
230.4 (1.2) 26.4 (2.0)
SACOL2694 geh Lipase 19.4 (1.4) 3.7 (1.3) 24.4 (1.5)
SA1817
f sec3 Enterotoxin type C3 10.9 (3.0) 26.9 (2.4)
SA1819
f tst Toxic shock syndrome toxin-1 15.2 (5.5) 28.3 (5.7)
Probable prophage or genomic island genes of unknown significance
SACOL0325
g Prophage L54a, antirepressor, putative 223.8 (2.2) 29.9 (2.0)
SACOL0326
g Hypothetical protein 226.4 (2.4) 215.7 (2.2)
SAOUHSC_02028
e QETA ORF57-like protein 222.6 (1.9) 225.5 (1.4)
SAOUHSC_02078 QPV83 orf 10-like protein 220.0 (2.0) 210.4 (1.8)
SAOUHSC_02206 Hypothetical phage protein 210.4 (1.6) 29.5 (1.6)
SAV0859
h Hypothetical protein 217.1 (1.7) 28.0 (2.3)
ig_SAV0860
h Intergenic region downstream of SAV0860 214.2 (1.8) 210.7 (1.9)
SAV0905
h Similar to QETA ORF57-like protein 222.6 (1.9) 225.5 (1.4)
SAV1985
i Hypothetical protein 217.4 (1.9) 211.5 (2.0)
a ORFs were identified by BLAST analysis of Affymetrix array target sequences, as described in the materials and methods. If a corresponding ORF was identified in S.
aureus COL, that strain’s ORF identifiers were used as default. SACOL####, S. aureus COL (GenBank accession number CP000046.1); SAV####, S. aureus Mu50
(BA000017.4); SA####, S. aureus N315 (BA000018.3); SAOUHSC_####, S. aureus NCTC 8325 (CP000253.1). Vertical lines indicate genes computationally predicted to
be in the same transcriptional unit. Gene names in brackets were assigned in this study using data shown in Table S1.
b Fold change in expression of genes during S. aureus SA564 growth in AH as compared to growth in glucose-supplemented CDM; a positive number indicates an up-
regulation of the gene during growth in AH. Standard deviation is shown in parentheses. Fold changes $3a n d,10 are shown and italicized.
c Fold change in expression of genes during S. aureus SA564 growth in VH as compared to growth in glucose-supplemented CDM; a positive number indicates an up-
regulation of the gene during growth in VH. Standard deviation is shown in parentheses. Fold changes $3 and ,10 are shown and italicized.
d Fold change in expression of genes during S. aureus SA564 growth in VH as compared to growth in AH; a positive number indicates an up-regulation of the gene
during growth in VH. Standard deviation is shown in parentheses. Fold changes $3a n d,10 are shown and italicized.
e At least two differentially expressed probe sets were assigned to these ORFs. Data for all probe sets are shown in Table S1.
f On genomic island vSA4 [48].
g On QCOL [48].
h On QSa1 [48].
i On QSa3 [48].
doi:10.1371/journal.pone.0110872.t002
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GeneChip was designed using genome sequence from the S.
aureus strains N315, Mu50, NCTC 8325, and COL, and queries
over 3300 ORFs and intergenic regions [30]. Genome sequence
data are not available for S. aureus SA564. For transcriptome
experiments with wild-type SA564 and its isogenic codY mutant
CDM7 (discussed further below), we obtained statistically signif-
icant hybridization over the background for an average of 64.8%
of probe sets (range, 57–71.8% over 12 chips), corresponding to
,3763 probe sets queried.
We performed three comparative analyses of wild-type S.
aureus SA564 transcriptomes: AH-grown cells compared to
CDM-grown cells (to model growth of S. aureus in the anterior
chamber), VH-grown cells compared to CDM-grown cells (to
model growth of S. aureus in the posterior chamber), and VH-
grown cells compared to AH-grown cells (to model transcriptional
changes potentially occurring after translocation of S. aureus from
the anterior to posterior chambers). A fold change cut-off of 10
was used to consider the most highly differentially regulated genes
in each condition. For the S. aureus GeneChip, probe set IDs (for
example, sa_c10261s8939_a_at) are used instead of gene names or
ORF assignments. To convert differentially expressed probe set
IDs to meaningful S. aureus genomic loci, we compared target
DNA sequences corresponding to differentially expressed probe
sets to S. aureus sequences in GenBank (see Materials and
Methods).
A total of 78 unique probe sets corresponding to 72 ORFs,
regulatory RNAs and intergenic regions were differentially
regulated at least 10-fold across the three comparisons (Table 2
and Table S1). Table S1 is an expanded version of Table 2
showing probe set IDs, BLAST hit distribution among S. aureus
COL, Mu50, N315, and NCTC 8325 genomes, and fold change
data for every gene shown in Table 2, irrespective of meeting the
fold change cut-off of 10. Fold changes $3 and ,10 are also
shown in Table 2 and are italicized. Two probe sets identified as
being differentially regulated in the VH versus CDM analysis,
sa_i7808d_x_at and sa_i9119u10r_x_at, query similar sequence at
non-syntenic regions of multiple S. aureus genomes and could not
be assigned to a single genomic locus (Table S1). Eleven of the
differentially expressed probe sets identified for the two compar-
isons using CDM-grown cells as controls had high standard
deviations (Table S1). Further investigation of the CDM control
arrays revealed that those 11 probe sets were themselves
differentially expressed between the two CDM controls (Table
S1). Data for those 11 probe sets are shown only in Table S1. No
other potential conflicts were detected in the control CDM arrays.
The differentially expressed genes identified by our microarray
analysis can be divided into three categories: (1) genes putatively
involved in transport or metabolism of nutrients; (2) putative or
confirmed virulence and/or biofilm factors; and (3) probable
prophage or genomic island genes of unknown significance.
Perhaps not surprisingly, most differentially expressed genes in the
analysis were assigned to the first category.
Several putative transcriptional units are highly up-regulated
during growth in AH as compared to CDM, and are also down-
regulated during VH growth compared to AH, suggesting that the
corresponding carbon substrates may be specific to or more
abundant in AH. These include SACOL0308-0310, putatively
involved in pseudouridine transport and catabolism; SA-
COL0311-0312, encoding an operon required for sialic acid
catabolism in S. aureus [30]; and SACOL0400-0403, putatively
involved in ascorbate uptake. In addition to these genes,
SACOL0176-0179, SACOL0192-0195, and SACOL0200 are
upregulated during growth in AH, and each appear to involved in
the uptake of and transcriptional response to sugars or
phosphosugars (Table S1).
We additionally identified genes putatively involved in lysine
biosynthesis from aspartate (SACOL1360, bioA, bioD) and
gluconeogenesis (gpm, SACOL2527) as being up-regulated during
growth in both AH and VH as compared to CDM, suggesting that
their regulation is specific to growth in ocular fluids. Another gene
putatively involved in gluconeogenesis, gapA2, was also differen-
tially regulated, but its up-regulation was specific to AH growth.
We also observed differential regulation of a set of putative
prophage and/or genomic island genes (Table 2). Interestingly, all
of these genes were down-regulated in both AH and VH relative
to growth in CDM, suggesting that increased expression of these
genes is CDM-specific. The significance of this is unknown.
Additionally, because genome sequence is not available for SA564
and thus the extent of its accessory genome is unknown, we cannot
exclude the possibility of AH- and/or VH-specific differential
regulation of prophage, plasmid and island genes that are not
represented on the S. aureus Affymetrix chip.
Our microarray analysis was verified using semiquantitative
RT-PCR to verify expression of a few genes discussed including
tst, cidA and nanA (Figure 2). A more intense signal was observed
for tst and nanA from AH samples when compared to CDM, and
cidA signal was more intense in VH when compared to CDM.
The results are consistent with the differential regulation of those
genes in our microarray analysis.
The S. aureus SA564 codY mutant in CDM, AH, and VH
We speculated that codY might have a role in ocular infections
given the presence of leucine, isoleucine and valine in human AH
and VH [16,17,31,32] and given the possibility that those
substrates might become depleted during in vivo S. aureus
growth. We first explored the effect of codY deletion on SA564
transcriptional responses to CDM, bovine AH and bovine VH,
using the previously described SA564 codY-mutant strain, CDM7
[29]. Using GeneChip analysis, we identified 130 probe sets as
being differentially expressed $5-fold, corresponding to 125
Figure 2. Semi-quantitative RT-PCR. Differential expression of tst,
nanA and cidA in AH, VH and CDM. clpX was used as a constitutively
expressed control gene.
doi:10.1371/journal.pone.0110872.g002
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ORF






b VH Fold change
b
SA1817 sec3 Enterotoxin type C3 6.7 (1.2)
SACOL0136 cap5A Capsular polysaccharide biosynthesis protein Cap5A 8.0 (1.6)
SACOL0138 cap5C Capsular polysaccharide biosynthesis protein Cap5C 6.2 (1.9)
SACOL0185 Peptide ABC transporter permease 53.8 (1.3) 6.5 (1.9) 11.5 (1.2)
SACOL0186 Peptide ABC transporter permease 31.5 (1.2) 5.9 (1.9) 10.9 (1.1)
SACOL0187 RGD-containing lipoprotein 29.3 (1.3) 11.9 (1.1)
SACOL0188 ggt c-glutamyltranspeptidase 13.0 (1.2) 7.1 (1.1)
SACOL0214 Long-chain-fatty-acid-CoA ligase 6.3 (2.4)
SACOL0215 Propionate CoA-transferase 8.4 (1.5)
SACOL0222 ldh1 L-lactate dehydrogenase 7.9 (2.2)
SACOL0267 Hypothetical protein 7.2 (1.0)
SACOL0270 Staphyloxanthin biosynthesis protein 6.5 (1.4)
SACOL0271 Hypothetical protein 5.3 (1.1)
SACOL0274 Hypothetical protein 5.0 (3.2)
SACOL0308
c Carbohydrate kinase (39 region) 27.2 (1.7)
SACOL0309 Hypothetical protein 26.8 (1.7)
SACOL0310 Nucleoside permease NupC 27.2 (2.0)
SACOL0427 Hypothetical protein 7.5 (1.1)
SACOL0428 metE 5-methyltetrahydropteroyltriglutamate/homocysteine
S-methyltransferase
19.7 (1.2) 9.2 (1.6)
SACOL0429 Bifunctional homocysteine
S-methyltransferase/5,10-methylenetetrahydrofolate reductase
28.3 (1.2) 11.5 (1.4)
SACOL0430 Trans-sulfuration enzyme family protein 36.1 (1.1) 12.8 (1.1)
SACOL0431 Trans-sulfuration enzyme family protein 30.9 (1.1) 10.4 (1.1)
SACOL0431 rev comp Reverse complement of interior
105 nt region of SACOL0431
11.1 (1.4)
ig_SACOL0431-2 121 nt region upstream of SACOL0431 12.3 (1.7)
SACOL0480 Hypothetical protein 9.7 (1.2)
SACOL0502 Cysteine synthase/cystathionine beta-synthase 7.6 (2.0)
SACOL0503
c metB Cystathionine c-synthase 7.1 (2.0)
SACOL0504 ABC transporter ATP-binding protein 30.4 (2.1)
SACOL0505 ABC transporter permease 29.3 (2.4)
SACOL0506 ABC transporter substrate-binding protein 18.4 (1.5)
SACOL0514 gltB Glutamate synthase 23.4 (1.3) 12.1 (1.5)
SACOL0515 gltD Glutamate synthase, small subunit 15.7 (1.3) 9.8 (1.2)
ig_SACOL0701-2 rev comp Reverse complement of intergenic
region between SACOL0701-2; 59
106 nt overlap RsaD sRNA from
Geissmann, et al. 2009 Nucleic Acids Res
20.4 (2.1) 5.4 (1.4) 9.2 (1.4)
SACOL0796 Iron compound ABC transporter permease 25.5 (2.3)
SACOL0797 Iron compound ABC transporter permease 25.8 (2.0)
SACOL0798 Iron compound ABC transporter ATP-binding protein 26.0 (2.3)
SACOL0815 Ribosomal subunit interface protein 5.5 (1.7)
SACOL0860 nuc Thermonuclease precursor 9.2 (1.2) 5.3 (1.3)
SACOL0991 oppB Oligopeptide ABC transport permease 10.7 (1.3)
SACOL0992 oppC Oligopeptide ABC transporter permease 11.5 (1.4)
SACOL0993 oppD Oligopeptide ABC transporter ATP-binding protein 8.3 (1.3)
SACOL0994 oppF Oligopeptide ABC transporter ATP-binding protein 7.9 (1.2)
SACOL0995 Oligopeptide ABC transporter oligopeptide-binding protein 8.3 (1.2)
SACOL1018 Sodium:alanine symporter family protein 21.9 (1.2) 9.9 (3.4) 15.7 (1.7)
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b VH Fold change
b
ig_SACOL1018-9 Intergenic region between
SACOL1018 and SACOL1019
12.3 (1.7) 21.9 (3.7)
SACOL1019 Hypothetical protein 6.1 (1.1)
SACOL1033 Hypothetical protein 8.9 (1.5)
SACOL1038 Membrane protein 9.5 (1.2) 6.3 (2.1) 12.3 (1.3)
SACOL1039 Hypothetical protein 7.0 (1.2) 5.6 (1.6) 13.0 (1.5)
SACOL1040 ABC transporter ATP-binding protein 9.4 (1.5) 7.6 (2.0) 8.4 (1.6)
SACOL1186 Antibacterial protein (phenol soluble modulin) 6.8 (2.6)
SACOL1187 Antibacterial protein (phenol soluble modulin) 6.8 (2.4)
SACOL1272
c codY Transcriptional repressor CodY 2789.6 (1.1) 2652.6 (1.4) 2197.4 (1.5)
SACOL1360 Aspartate kinase 30.4 (1.3)
SACOL1362 hom Homoserine dehydrogenase 16.3 (1.3)
SACOL1363 thrC Threonine synthase 17.5 (1.4)
SACOL1364 thrB Homoserine kinase 14.9 (1.3)
SACOL1368 katA Catalase 5.3 (1.7)
SACOL1403 trpE Anthranilate synthase component I 6.0 (1.4)
SACOL1404 trpG Anthranilate synthase component II 6.4 (1.5)
SACOL1405 trpD Anthranilate phosphoribosyltransferase 8.6 (1.6) 6.5 (1.1)
SACOL1406 trpC Indole-3-glycerol-phosphage synthase 13.7 (1.5) 7.7 (1.2)
SACOL1407 trpF N-(59-phosphoribosyl)anthranilate isomerase 21.9 (1.5) 10.0 (1.3)
SACOL1408 trpB Tryptophan synthase subunit b 18.4 (1.7) 6.7 (1.2)
SACOL1409 trpA tryptophan synthase subunit a 6.1 (1.4)
SACOL1428 lysC Aspartate kinase 10.9 (1.7)
SACOL1429 asd Aspartate semialdehyde dehydrogenase 14.2 (1.4)
SACOL1430 dapA Dihydrodipicolinate synthase 13.5 (1.2)




ig_SACOL1432-3 Intergenic region between dapD and
SACOL1433
26.4 (1.8)
SACOL1433 M20/M25/M40 family peptidase 9.2 (1.3)
SACOL1434 Alanine racemase 9.2 (1.2)
SACOL1449 sucA 2-oxoglutarate dehydrogenase E1 component 5.2 (1.1)
SACOL1772 Class V aminotransferase 24.3 (1.2) 5.4 (2.9) 13.7 (1.2)
SACOL1773 serA D-3-phosphoglycerate dehydrogenase 21.5 (1.3) 11.9 (1.2)
SACOL2003 hlb Queries 170 nt (positions 19–188) in
59 region of hlb (phospholipase C)
5.6 (1.3)
SACOL2021-2 RNAIII 39 345 nt of RNAIII; probes region
downstream of d-hemolysin gene
12.1 (3.2)
SACOL2022 hld d-hemolysin 10.4 (3.8)
SACOL2031 Ammonium transporter family protein 11.1 (1.3) 5.0 (1.9) 5.6 (1.2)
ig_SACOL2041-2 Intergenic region upstream of
SACOL2042 ilvD (ilvD promoter
region)
23.4 (4.3)
SACOL2042 ilvD Dihydroxy-acid dehydratase 48.5 (1.4) 11.3 (5.4) 26.4 (1.4)
SACOL2043 ilvB Acetolactate synthase large subunit 80.2 (1.2) 39.4 (1.2)
SACOL2044 Acetolactate synthase 1 regulatory subunit 157.6 (1.7) 8.6 (3.1) 85.9 (1.4)
ig_SACOL2044-5 Intergenic region between SACOL2044 and ilvC 33.7 (1.3)
SACOL2045 ilvC Ketol-acid reductoisomerase 100.4 (1.3) 5.3 (2.2) 61.8 (1.3)
SACOL2046 leuA 2-isopropylmalate synthase 109.5 (1.2) 64.0 (1.3)
SACOL2047 leuB 3-isopropylmalate dehydrogenase 89.0 (1.3) 5.2 (2.3) 64.0 (1.4)
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b
SACOL2048 leuC Isopropylmalate isomerase large subunit 95.3 (1.2) 62.9 (1.4)
SACOL2049 leuD Isopropylmalate isomerase small subunit 107.6 (1.2) 5.2 (1.7) 76.1 (1.2)
SACOL2050 ilvA2 Threonine dehydratase 78.8 (1.2) 5.2 (1.9) 41.5 (1.2)
SACOL2314 Sodium/bile acid symporter family protein 7.7 (1.1)
SACOL2403 ABC transporter substrate-binding protein 25.5 (1.4)
SACOL2554.1 LrgA family protein 25.0 (1.5)
SACOL2585 Hypothetical protein 20.0 (1.2) 7.7 (2.8) 10.2 (1.5)
ig_SACOL2585-4 Intergenic region downstream of SACOL2585 6.1 (1.1)
SACOL2619 Amino acid permease 19.0 (1.2) 6.6 (2.9) 9.2 (1.7)
SACOL2620 4-aminobutyrate aminotransferase 29.3 (1.3) 9.0 (3.6) 16.0 (1.5)
ig_SACOL2620-1 Intergenic region upstream of SACOL2620 34.3 (1.3) 7.9 (3.4) 20.4 (2.1)
SACOL2627 betA Choline dehydrogenase 5.0 (2.4)
SACOL2628 betB Betaine aldehyde dehydrogenase 5.4 (2.4)
SACOL2641 gpxA2 Glutathione peroxidase 6.4 (1.4)




ig_SACOL2641-2 rev comp Reverse complement of intergenic
region between SACOL2642 and
gpxA2
6.5 (1.8)
SACOL2659 aur Zinc metalloproteinase aureolysin 12.3 (1.6) 5.1 (1.4) 9.2 (1.5)
SACOL2689 icaA N-glycosyltransferase 6.7 (1.1)
SACOL2690 icaD Intercellular adhesion protein D 7.5 (1.3)
ig_SACOL2695-6 Intergenic region between
SACOL2696 (hisI) and SACOL2695
18.7 (1.5) 6.0 (1.5)
SACOL2696 hisI Bifunctional phosphoribosyl-AMP
cyclohydrolase/phosphoribosyl-ATP
14.7 (1.2) 11.5 (1.3)
SACOL2697 hisF Imidazole glycerol phosphate
synthase subunit HisF
16.6 (1.2) 12.3 (1.2)
SACOL2698 hisA 1-(5-phosphoribosyl)-5-((5-phosphoribosylamino)methylideneamino)
imidazole-4-carboxamide isomerase
16.9 (1.2) 18.4 (1.4)
SACOL2699 hisH Imidazole glycerol phosphate synthase subunit HisH 20.7 (1.1) 14.9 (1.5)
SACOL2700 hisB Imidazoleglycerol-phosphate dehydratase 22.2 (1.0) 13.9 (1.2)
SACOL2701 Histidinol-phosphate aminotransferase 24.2 (1.1) 16.9 (1.2)
SACOL2702 hisD Histidinol dehydrogenase 24.3 (1.1) 14.9 (1.1)
SACOL2703 hisG ATP phosphoribosyltransferase catalytic subunit 27.9 (1.1) 11.5 (1.2)
SACOL2704 hisZ ATP phosphoribosyltransferase regulatory subunit 23.0 (1.1) 16.9 (1.1)
ig_SACOL2704-5 Intergenic region between SACOL2705-4 11.7 (1.9) 8.7 (1.5)
SACOL2705 Hypothetical protein 13.9 (1.3) 10.9 (1.1)
ig_SACOL2705-6 Intergenic region between SACOL2706-5 6.1 (1.8)
SACOL2706 Hypothetical protein 18.7 (1.1) 19.4 (1.5)
SACOL2707 Cobalt transport family protein 20.0 (1.2) 16.9 (1.3)
SACOL2708 ABC transporter ATP-binding protein 30.4 (1.3) 19.7 (1.1)
SACOL2709 Hypothetical protein 31.5 (1.5) 13.5 (1.3)
SACOL2710 Hypothetical protein 59.7 (1.3) 8.6 (3.6) 24.7 (1.3)
a ORFs were identified by BLAST analysis of Affymetrix array target sequences, as described in the materials and methods. If a corresponding ORF was identified in S.
aureus COL, that strain’s ORF identifiers were used as default. SACOL####, S. aureus COL (GenBank accession number CP000046.1); SAV####, S. aureus Mu50
(BA000017.4); SA####, S. aureus N315 (BA000018.3); SAOUHSC_####, S. aureus NCTC 8325 (CP000253.1).
b Fold change in expression of genes by S. aureus CDM7 as compared to the wild-type strain during growth in the indicated medium; a positive number indicates an up-
regulation of the gene by the codY mutant. Standard deviation is shown in parentheses.
c At least two differentially expressed probe sets were assigned to these ORFs. Data for all probes sets are shown in Table S2.
doi:10.1371/journal.pone.0110872.t003
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Table S2).
Genes differentially regulated by the S. aureus SA564 codY
mutant as compared to the wild-type strain during exponential
growth in CDM are similar to those previously identified for S.
aureus Newman (1) and S. aureus UAMS-1 (2) codY mutants
during exponential growth in a chemically defined medium and
tryptic soy broth, respectively (Table S2). As for Newman and
UAMS-1, codY inactivation in SA564 results in an up-regulation of
amino acid metabolic and virulence genes including BCAA
metabolism (ilvDBC, leuABCD, ilvA), hemolysins (hlb, hld), and
phenol-soluble modulins (SACOL1186, SACOL1187). As expect-
ed based on previous studies on CodY regulation in SA564 [29],
we observed up-regulation of icaA, RNAIII and hld. We also
identified expression of an enterotoxin, capsular polysaccharide
biosynthesis proteins, metalloproteinase aureolysin and others as
being affected by codY deletion. All other genes are shown in
Table 3. Interestingly, of 117 ORFs, regulatory RNAs and
intergenic regions identified as being differentially regulated in
CDM when comparing S. aureus codY-mutant to SA564, all but
one (SA1817, the enterotoxin gene) are core to the four S. aureus
strains used to generate the GeneChip (Table S2) [33]. However,
it is possible that as yet unknown S. aureus SA564-specific genes
are under CodY control.
Of the 117 ORFs, regulatory RNAs and intergenic regions
identified as being differentially regulated in the SA564 codY
mutant relative to the wild-type strain during growth in CDM, 55
of those were also identified as being differentially regulated during
growth in VH (Table 3 and Table S2). Of the 117, only 23 were
identified as being differentially regulated during growth in AH.
We were curious as to why this expression pattern was observed in
AH, and whether it could be explained by a relief of CodY
repression occurring during growth in AH at the cell density
chosen for our microarray experiments. To explore this further,
we returned to the microarray analysis of the SA564 wild-type
strain grown in AH, as compared to CDM. Expression data for all
differentially expressed genes for the SA564 codY mutant during
growth in CDM were extracted from each of the four SA564 AH
versus CDM analyses (Table S2). Analysis of these data revealed
that genes previously identified as being under CodY control
[1,2,5,29] were de-repressed in one AH sample (AH2), but not the
other (AH1), relative to CDM (Table S2), most likely as a result of
BCAA becoming depleted from the pooled AH2 sample.
Speculatively, these data suggest that, in vivo in the anterior
chamber, where BCAA are present [16,31], CodY repression may
limit virulence of S. aureus during early stages of infection when
cell densities are likely to be low. Future studies that track BCAA
concentrations and expression of CodY-regulated genes in ex vivo
AH samples over the course of S. aureus growth could be used to
explore this further.
We additionally observed AH-specific up-regulation of lrgAB
and VH-specific up-regulation of cidA. lrgAB and cidA are
involved in coordination of cell death and autolysis, in addition to
their role in biofilm development through the release of genomic
DNA that becomes a structural component of the biofilm matrix.
Note that lrgAB expression varied between the two AH gene
expression experiments, with low albeit significant up-regulation
observed during growth in one AH sample (1.4–2.6 fold up-
regulated compared to CDM controls), and comparatively higher
up-regulation during growth in another AH sample (17.1–27.8-
fold up-regulated compared to CDM controls).
codY deletion enhances S. aureus virulence in a murine
AC infection model
To assess a potential role for CodY in endophthalmitis, we
began by examining the potential for intraocular growth of S.
aureus after injection into the murine AC. Approximately 5610
3
CFU of S. aureus SA564 or codY-mutant were injected into the
murine AC, and bacterial growth was assessed after 24 h by
extraction and homogenization of the entire eye (Table 4). In all
cases, viable S. aureus were recovered (SA564 range, 4610
2–2.3–
10
6 CFU; codY mutant range, 1610
2–1.3610
6 CFU). Average
in vivo growth yields of SA564 and CDM7 were similar (4.6610
5
CFU for SA564; 2610
5 CFU for CDM7). Thus, after introduction
Table 4. S. aureus SA564, CDM7 and MS7 in vivo growth yields.
SA564 CDM7 MS7
Inoculum (CFU) 24 h (CFU)
a Inoculum (CFU) 24 h (CFU)






















































a Number of CFU recovered per homogenized eye is shown. Each entry represents one eye.
b ND, Not detected. The limit of detection for these experiments was 1610
2 CFU.
doi:10.1371/journal.pone.0110872.t004
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environment for the survival of each strain. Because the entire eye
was homogenized for these experiments, it is unknown whether
growth occurred in the anterior chamber, the posterior chamber,
or both.
We next assessed the impact of codY on inflammation (Fig. 3A)
and retinal responsiveness (Fig. 3B) at 24 h after infection. The
distribution of inflammation scores were significantly different for
eyes infected with the two strains (p,0.001; one-tailed Wilcoxon
rank-sum test), with a higher average inflammation score for the
codY mutant (3.6 versus 2.1) (Fig. 3A). Average retinal respon-
siveness was lower for eyes inoculated with the codY mutant (45%
of control versus 80% of control), and the distribution of percent
retinal responsiveness values was significantly different between
eyes infected with the codY mutant and those infected with SA564
(p=0.001, one-tailed Wilcoxon rank-sum test) (Fig. 3B). Repre-
sentative histology images are shown in Fig. 4. As seen in the
figure, the eye infected with the codY mutant shows more
inflammation in the cornea, anterior chamber, and vitreous, as
well as disruption of retinal architecture. Collectively, these data
suggest that CodY regulation of its target genes limits S. aureus
disease in the murine anterior chamber infection model.
Similar experiments were performed using previously described
MS7, codY complemented strain [29]. In this vector, codY
expression is under the control of a leaky IPTG-inducible
promoter (PSPAC) [29]. codY expression from pTL6936 appears
to be leaky, as partial complementation was observed for an S.
aureus UAMS-1 codY mutant in the absence of IPTG [34]. We
observed increased retinal responsiveness and decreased inflam-
mation as assessed by slitlamp for murine eyes inoculated with
10
3–10
4 CFU MS7, compared to SA564 and CDM7 (Fig. 4A–B),
suggesting that in vivo complementation of the codY occurred.
However, decreased in vivo growth yields were observed for MS7
compared to SA564 and CDM7 (Table 4; range, ,100–2.5610
5
CFU; average, 1.9610
4 CFU). Thus it is unknown whether the
increased retinal responsiveness and decreased inflammation
observed for MS7 were due to complementation of the codY
lesion or to an in vivo growth defect of this strain. MS7 does not
have an in vitro growth defect relative to CDM7 as assessed by
growth in CDM; the average doubling time of MS7 is
49.060.5 min, compared to 50.760.3 min for CDM7 (Fig. 1).
Discussion
CodY controls expression of virulence and metabolic genes in
response to branched-chain amino acids (BCAA) and GTP. This
makes it an important regulatory link between nutrient availability
and virulence factor production [1]. However, little is known
about its contribution to virulence in vitro and in vivo in the
ocular milieu.
AH is a complex mixture of electrolytes, organic solutes, growth
factors, cytokines, and proteins including BCAA that provide the
metabolic requirements to the avascular tissues of the anterior
segment. It is produced from the non-pigmented ciliary body
epithelium through simple diffusion as well as active transport of
ions and solutes and exits the anterior chamber mainly via the
trabecular meshwork. The volume of human AH in the anterior
chamber generally turns over once every 100 minutes replenishing
nutrients that have been taken up by avascular ocular tissues and
carries away metabolic wastes [16,17,31].
In this study, we demonstrated that bovine AH and VH provide
adequate nutrition for growth of S. aureus SA564, and result in
differential gene expression when compared to each other, and to
a defined medium. While our in vitro bovine AH and VH models
lack the nutritional replenishment and immune response that
would be characteristic of in vivo growth environments, the
models are useful in that they allow for the identification of
nutrients that S. aureus specifically detects and responds to in the
ocular milieu, in particular, sialic acid, ascorbate, and pseudouri-
dine.
Pseudouridine is a nucleoside present in RNAs of humans and
other animals [32]. It has been detected in tRNAs of the bovine
lens [34]. SACOL0308, SACOL0309, and SACOL0310 share
protein sequence homology and conserved protein domains with
Figure 3. Inflammation and retinal responsiveness in S. aureus
infected eyes. Inflammation scores (A) and % retinal responsiveness
(B) for murine eyes infected with SA564, CDM7, or MS7, assessed 24 h
post-inoculation. Average values are indicated by heavy black
horizontal lines. *, p#0.001, Mann-Whitney test.
doi:10.1371/journal.pone.0110872.g003
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coli (Table S1) [35]. YeiC is a pseudouridine kinase, and YeiN is a
pseudouridine-59-phosphate glycosidase. Together, YeiC and
YeiN comprise a pathway for the catabolism of pseudouridine to
uracil and ribose-5-phosphate [35]. YeiM is a predicted nucleoside
transporter and may be involved in uptake of pseudouridine from
the environment. It is possible that S. aureus SA564 catabolizes
pseudouridine for energy (via ribose-5-phosphate), and/or for
uracil scavenging in AH.
N-acetylneuraminate, another highly upregulated gene in AH,
is the primary sialic acid moiety present in mammalian tissues, and
sialic acid modification of human cell surfaces is used as a ‘‘self
versus non-self’’ signal to the immune system, allowing for
discrimination of cell types, among other functions of sialic acids
[36]. In the eye, sialic acid is distributed in all structures, including
cornea, sclera, AH, trabecular meshwork, lens, VH and retina,
and its concentration seems to increase with aging [37].
SACOL0312 and SACOL0311 encode a putative sodium:solute
symporter protein (NanT) and N-acetylneuraminate lyase (NanA),
respectively. NanA converts N-acetylneuraminate to N-acetyl-
mannosamine and pyruvate [38]. Recently, it was shown that
nanA and nanT are co-transcribed in S. aureus strain AH1263
[30]. Further, nanA and nanT are required for S. aureus growth
with sialic acid [30]. Our microarray results suggest that S. aureus
SA564 transports and catabolizes sialic acid during growth in
bovine AH.
Ascorbate (vitamin C) is abundant in the eye and present at
much higher concentrations than in the plasma [39]. It is actively
transported by the iris-ciliary body into the AH and serves as an
antioxidant to protect the eye against light-induced free radical
damage [40]. SACOL0400-SACOL0403 encode a putative
ascorbate uptake transport system (ulaABC) and a predicted
transcriptional antiterminator (Table 2 and Table S1). In E. coli,
the PTS-like UlaABC system (alternatively named SgaTBA)
transports ascorbate with concomitant phosphorylation, trapping
ascorbate-6-phosphate in the cell [41]. S. aureus may transport
ascorbate to prevent Fenton reaction damage occurring as a result
of extracellular iron reduction by ascorbate under aerobic
conditions [42].
Several virulence factors were specifically up-regulated during
growth in AH, including an enterotoxin (sec3), the toxic shock
syndrome toxin (tst), and a phenol soluble modulin (Table 2). The
toxic shock syndrome toxin and the SEC enterotoxin are
superantigens that are important in infections such as infective
endocarditis and pneumonia [43–45]. Immunization against those
exotoxins was found to protect against those serious illnesses
[44,46]. Phenol soluble modulins have also been found in animal
models to have an essential role in bacteremia and skin infections
[47]. The AH-specific up-regulation of these factors may facilitate
translocation of S. aureus or S. aureus-produced factors into the
posterior chamber and/or retinal damage during S. aureus
endophthalmitis.
As for the analysis of the codY mutant, our microarray results
demonstrate that codY deletion impacts expression of metabolic
and virulence genes in S. aureus SA564. However, genes affected
by codY were not consistent across the two pooled AH samples
used here, suggesting that BCAA became depleted from one of the
samples. These data indicate that, in vivo in the AC, where BCAA
are present and replenished by AH turnover continuously, CodY
repression may limit virulence of S. aureus during early stages of
infection when cell densities are likely to be low. Consistent with
this proposal, deletion of codY enhanced virulence of S. aureus in a
murine AC infection model, as assessed by retinal function
measurements, degree of inflammation in the eye, and histological
assessments of ocular tissue damage. The microarray results
suggest a role for enterotoxin (sec3), the toxic shock syndrome
toxin (tst), and a phenol soluble modulin in endophthalmitis
progression. Collectively, these data suggest that CodY repression
of its target genes limits S. aureus disease in the murine AC
infection model.
In conclusion, we used novel in vitro and in vivo infection
models to characterize the behavior of S. aureus during
endophthalmitis, one a nutritional model utilizing bovine ocular
fluids as media for S. aureus growth ex vivo, and one an in vivo
infection model evaluating endophthalmitis progression after S.
aureus injection into the murine AC. We identified metabolic
pathways that may be important for S. aureus endophthalmitis,
specifically sialic acid, ascorbate, and pseudouridine metabolism.
We are now directly assessing the roles of these pathways in the
pathogenesis of S. aureus endophthalmitis. We additionally
identified several virulence factors whose expression was activated
by growth in ocular fluids, suggesting that transcriptional
Figure 4. Histology images. Representative histology images of S. aureus SA564- and CDM7-infected eyes at 24 h post-inoculation. Retinal
responsiveness values for the infected eyes shown were 95.9% (SA564) and 11.9% (CDM7). Panels shown, from top to bottom, are the whole eye, the
AC, and the retina.
doi:10.1371/journal.pone.0110872.g004
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in the eye. Our in vivo endophthalmitis model, a murine AC
infection model, revealed a link between the BCAA-responsive
transcriptional regulator CodY and experimental endophthalmitis
progression. More specifically, relief of CodY repression of its
target genes (by deletion of codY) enhanced S. aureus pathogenesis
in the murine eye. Interestingly, this result suggests that it may be
possible to use BCAA to mitigate S. aureus endophthalmitis
progression by supplementing BCAA in eye drops postoperatively
or by adding BCAA to the infusion solution that goes through the
eye during intraocular surgery.
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